drug

rezafungin

1 story · latest Aug 13, 2026

Status: FDA approved Mar 2023 · NDA217417
Brand: Rezzayo

Relationships

Developed by Mundipharma

Timeline

CorMedix reports Q2 2026 results, flags REZZAYO filing and DefenCath supply deal

Aug 13Quarterly updateCorMedix Inc.rezafungin

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.